{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:08:28Z","timestamp":1790251708113,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03110-1","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:38:33Z","timestamp":1786437513000},"page":"2372-2376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-4470","authenticated-orcid":false,"given":"Lin Pierre","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Berthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2808-4843","authenticated-orcid":false,"given":"Laurene","family":"Fenwarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8126-4942","authenticated-orcid":false,"given":"Stephane","family":"De Botton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6745-1127","authenticated-orcid":false,"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Farnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Arnautou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-1559","authenticated-orcid":false,"given":"Delphine","family":"Lebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Aljijakli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Plantier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ollivier","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5142-0310","authenticated-orcid":false,"given":"Juliette","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9814-8537","authenticated-orcid":false,"given":"Christophe","family":"Willekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3925-7391","authenticated-orcid":false,"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bories","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Lemasle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin-James","family":"Wattebled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-7920","authenticated-orcid":false,"given":"Ambroise","family":"Marcais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Salanoubat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Turlure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamile","family":"Frayfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Uzunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Garidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Vaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Buffet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Celli-Lebras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-6262","authenticated-orcid":false,"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-1022","authenticated-orcid":false,"given":"Nicolas","family":"Duployez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-8766","authenticated-orcid":false,"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"3110_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet Lond Engl. 2023;401:2073\u201386.","journal-title":"Lancet Lond Engl"},{"key":"3110_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2025-6","volume":"146","author":"A Fathi","year":"2025","unstructured":"Fathi A, Perl A, Fell G, Jonas B, Ragon B, Mims A, et al. Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood. 2025;146:6.","journal-title":"Blood"},{"key":"3110_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"3110_CR4","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481\u20135.","journal-title":"Blood"},{"key":"3110_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1182\/blood.2021011103","volume":"138","author":"R Itzykson","year":"2021","unstructured":"Itzykson R, Fournier E, Berthon C, R\u00f6llig C, Braun T, Marceau-Renaut A, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138:507\u201319.","journal-title":"Blood"},{"key":"3110_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"3110_CR7","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1200\/JCO.23.02631","volume":"42","author":"J Versluis","year":"2024","unstructured":"Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen NA, et al. Risk stratification in older intensively treated patients with AML. J Clin Oncol. 2024;42:4084\u201394.","journal-title":"J Clin Oncol"},{"key":"3110_CR8","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169\u201373.","journal-title":"Blood"},{"key":"3110_CR9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","volume":"8","author":"A Bataller","year":"2024","unstructured":"Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, et al. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024;8:927\u201335.","journal-title":"Blood Adv"},{"key":"3110_CR10","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/blood.2024026925","volume":"144","author":"CA Lachowiez","year":"2024","unstructured":"Lachowiez CA, Ravikumar VI, Othman J, O\u2019Nions J, Peters DT, McMahon C, et al. Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML. Blood. 2024;144:2788\u201392.","journal-title":"Blood"},{"key":"3110_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41375-024-02501-6","volume":"39","author":"R Shahswar","year":"2025","unstructured":"Shahswar R, Gabdoulline R, Krueger K, Wichmann M, G\u00f6tze KS, Braitsch K, et al. A novel prognostic risk model for patients with refractory\/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. Leukemia. 2025;39:614\u201322.","journal-title":"Leukemia"},{"key":"3110_CR12","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1182\/bloodadvances.2019001349","volume":"4","author":"C Gardin","year":"2020","unstructured":"Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis J-H, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020;4:1942\u20139.","journal-title":"Blood Adv"},{"key":"3110_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100017","volume":"1","author":"J Othman","year":"2024","unstructured":"Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, et al. Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS. Blood Neoplasia. 2024;1:100017.","journal-title":"Blood Neoplasia"},{"key":"3110_CR14","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1182\/bloodadvances.2024015734","volume":"9","author":"L-P Zhao","year":"2025","unstructured":"Zhao L-P, Dumas-Rivero T, Barette L, Aguinaga L, Cheffai A, Chauvel C, et al. Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine. Blood Adv. 2025;9:3556\u201365.","journal-title":"Blood Adv"},{"key":"3110_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","volume":"636","author":"J Sango","year":"2024","unstructured":"Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G, et al. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature. 2024;636:241\u201350.","journal-title":"Nature"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03110-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:22Z","timestamp":1790250202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03110-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3110"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03110-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Approval was obtained from the Comit\u00e9 de Protection des Personnes (CPP) Ile-de-France X (GHT Grand Paris Nord-Est \u2013 CH Robert Ballanger, Aulnay-sous-Bois, France), reference number CPP 15-2021 (SI-RIPH2G 21.01097.152021).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All patients provided written informed consent for participation and data collection.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Ethics"}}]}}